Table: Towa Pharmaceutical - 6-MTH group results
Nov 10 (Reuters)-
Towa Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2025 Sep 30, 2024 Mar 31, 2026
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 130.48 123.40 280.00
(+5.7 pct) (+14.9 pct) (+7.9 pct)
Operating 10.44 10.51 27.00
(-0.7 pct) (+50.1 pct) (+16.2 pct)
Recurring 11.98 10.34 25.30
(+15.9 pct) (+1.0 pct) (-3.3 pct)
Net 8.21 6.56 17.70
(+25.3 pct) (-5.7 pct) (-6.8 pct)
EPS 166.86 yen 133.17 yen 359.57 yen
Ann Div 70.00 yen 80.00 yen
-Q2 div 40.00 yen 30.00 yen
-Q4 div 40.00 yen 40.00 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results